Application strategies of the third-generation EGFR-TKI in the context of precision medicine

J. Zhao, S. J. Zhang, C. C. Zhou

Research output: Contribution to journalArticlepeer-review

Abstract

随着分子检测技术的进步和靶向治疗药物的不断推出,肿瘤的诊疗已经进入到了精准化的全程管理时代。表皮生长因子受体(EGFR)作为最常见的驱动基因,其在中国非小细胞肺癌(NSCLC)患者中的阳性率约达50%。EGFR酪氨酸激酶抑制剂(EGFR-TKI)在NSCLC的临床治疗中扮演重要角色。第一代和第二代EGFR-TKI治疗已成为EGFR突变阳性晚期NSCLC患者的标准一线治疗,第三代EGFR-TKI也显示出良好的疗效,明显改善了晚期NSCLC患者的生存,提高了患者的生活质量。在精准医学背景下,第三代EGFR-TKI药物的应用策略值得关注。.

Original languageEnglish (US)
Pages (from-to)86-89
Number of pages4
JournalZhonghua zhong liu za zhi [Chinese journal of oncology]
Volume39
Issue number2
DOIs
StatePublished - Feb 23 2017

Keywords

  • Carcinoma, non-small-cell lung
  • Epidermal growth factor receptor
  • Precision medicine
  • Tyrosine kinase inhibitor

Fingerprint Dive into the research topics of 'Application strategies of the third-generation EGFR-TKI in the context of precision medicine'. Together they form a unique fingerprint.

Cite this